Abridged Unaudited Consolidated Financial Statements For The Quarter And Nine Months Ended 30 November 2018 GO LIFE INTERNATIONAL LIMITED (Incorporated in the Republic of Mauritius) (Registration number: 098177 C1/GBL) Primary Listing SEM share code: GOLI.N0000 Secondary Listing JSE share code: GLI ISIN: MU0330N00004 (“the Company” or “the Group” or “Go Life”) Abridged Unaudited Consolidated Financial Statements for The Quarter And Nine Months Ended 30 November 2018 DIRECTORS’ COMMENTARY BACKGROUND The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act and holds a Category 1 Global Business License (License No - C110009034) issued by the Mauritius Financial Services Commission. Go Life is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius (“SEM”) on 7 July 2011. The Company successfully completed a secondary listing on the Alternative Exchange (“AltX”) of the Johannesburg Stock Exchange (”JSE”) on 23 November 2016. PRIMARY OBJECTIVE The initial focus of the Company was to compete in the supplementary nutraceutical and cosmeceutical markets by offering natural compounds that have been subjected to study and clinical trials. The focus has shifted somewhat and Go Life is now a multi-faceted healthcare company, offering a comprehensive, all-inclusive product range to address market needs in the pharmaceutical, generic, nutraceutical and cosmeceutical markets. In addition, Go Life now offers a range of medicinal consumables and high end sophisticated hospital equipment. Being a nutraceutical company at heart, the advantages contained in medicinal cannabis could no longer be ignored. Go Life has positioned itself strategically to enter the cannabis cultivation market and in so doing, favourably positions itself to manufacture innovative and appropriate cannabis derived medicinal products. RESULTS COMMENTARY Revenue grew by 87.29% for the three months ended 30 November 2018 (“Q3”) to USD 2 380 389 compared to, USD 1 270 983 reported at the prior three-months ended 31 August 2018 (“Q2”). The growth in revenue is attributed to the performance and the continuous popularity of the nutraceutical range offered in Gotha. Pending negotiations on acquiring an elevated portion (currently 50%) is in process. An announcement in this regard is anticipated shortly. Profit from operations increased by 83.64% for Q3 to USD 894 716 from USD487 199 in Q2. Income from associates increased by 46.16% to USD 114 839 (Q3) from USD 78 569 (Q2) and is derived from the associate interest in Bon Health frail care operations. COMPANY OUTLOOK Go Life is currently in the process of incorporating medicinal cannabis into its nutraceutical products range. To this end, Go Life is at an advanced stage of negotiating a settlement to acquire a majority stake in Aziza Healthcare and the cultivating division known as Choice Organics. An announcement in this regard will follow soon. The potential acquisition of Aziza Healthcare favourably positions Go Life towards bringing innovative ways of accurately administering medicinal cannabis. Extensive research was conducted on developing channels for Gotha Health Products. To this end, Cosmetic Connection has been identified as an excellent channel for the Gotha range of products. Cosmetic Connection has 40 branches across South Africa and it is an ideal vehicle to introduce Gotha Health Products to a wider South African market. Go Life has also recently partnered with The Ingonyama Trust, which represents and manages King Goodwill Zwelithini kaBhekuzulu’s land in KwaZulu Natal, with the aim of increasing the Gotha Health Products preventative medical offering. The transaction with Ascendis Health Direct, as announced on 4 September 2018, has been delayed due to certain conditions precedent that have not yet been fulfilled. The parties are in the process of resolving the outstanding matters, which are expected to be finalised imminently. RELATED PARTY TRANSACTIONS There were no transactions with related parties that are material to an understanding of these results. DIVIDENDS No dividends were authorized or paid during the period under review. STATEMENT OF FINANCIAL POSITION THE GROUP THE GROUP THE GROUP THE GROUP Unaudited Unaudited Unaudited Audited 9 MONTHS 9 MONTHS 6 MONTHS 12 MONTHS 30 NOVEMBER 30 NOVEMBER 31 AUGUST 28 FEBRUARY 2018 2017 2018 2018 USD USD USD USD ASSETS Non - Current Assets 38 861 444 36 658 985 37 661 769 37 394 804 Investments in Associates 899 925 998 538 849 095 849 095 Intangible Assets 29 948 171 28 857 769 29 026 143 29 026 143 Property Plant and Machinery 8 013 348 6 802 678 7 786 531 7 519 566 Current Assets 1 286 729 1 088 572 1 313 558 856 012 Inventories 248 863 - 184 721 96 830 Trade and other Receivables 394 582 489 287 245 381 172 698 Cash and Cash Equivalents 643 284 599 285 883 456 572 724 Income taxes - - - 13 760 TOTAL ASSETS 40 148 173 37 747 557 38 975 327 38 250 816 EQUITY Capital and Reserves 35 650 562 34 482 637 34 953 410 34 478 762 Share Capital 34 965 300 34 965 300 34 965 300 34 965 300 Accumulated Profit 685 262 (482 663) (11 890) (486 538) Non Distributable Reserves - - - - Foreign Currency Translation Reserve - - - - LIABILITIES Non - Current Liabilities 4 207 759 2 988 122 3 612 296 3 424 785 Loan - Shareholders 3 487 325 2 988 122 3 487 325 3 424 784 Loan – third party 720 434 - 124 971 - Current Liabilities 289 852 276 798 409 623 347 269 Trade and other Payables 289 852 276 798 409 623 241 299 Income Tax - - - 105 970 TOTAL EQUITY AND LIABILITIES 40 148 173 37 747 557 38 975 327 38 250 816 STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME THE GROUP THE GROUP THE GROUP THE GROUP THE GROUP Unaudited Unaudited Unaudited Unaudited Audited 3 MONTHS 9 MONTHS 9 MONTHS 6 MONTHS 12 MONTHS 30 NOVEMBER 30 NOVEMBER 30 NOVEMBER 31 AUGUST 28 FEBRUARY 2018 2018 2017 2018 2018 USD USD USD USD USD Revenue 1 109 406 2 380 389 1 568 463 1 270 983 1 819 213 Expenses (701 889) (1 485 673) (898 764) (783 784) (1 015 261) PROFIT FROM OPERATIONS 407 517 894 716 669 699 487 199 803 952 Share of profits -Associates 36 270 114 839 95 612 78 569 190 565 Finance Income - - - - - Finance costs (105 422) (312 403) (213 192) (206 981) (313 103) PROFIT BEFORE TAXATION 338 365 697 152 552 119 358 787 681 414 Taxation - - - - (105 970) NET PROFIT AFTER TAXATION 338 365 697 152 552 119 358 787 575 445 Other Comprehensive income - - - - - TOTAL COMPREHENSIVE INCOME FOR THE PERIOD 338 365 697 152 552 119 358 787 575 445 RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS THE GROUP THE GROUP THE GROUP THE GROUP Unaudited Unaudited Unaudited Audited 9 MONTHS 9 MONTHS 6 MONTHS 12 MONTHS 30 NOVEMBER 30 NOVEMBER 31 AUGUST 28 FEBRUARY 2018 2018 2017 2018 2018 USD USD USD USD Basic earnings 697 152 515 668 358 787 575 445 Headline earnings 697 152 515 668 358 787 575 445 Weighted average number of shares 900 000 000 900 000 000 900 000 000 900 000 000 Basic and diluted earnings per share (USD cents) 0.0775 0.0572 0.0399 0.0639 Headline earnings per share (USD cents) 0.0775 0.0572 0.0399 0.0639 STATEMENT OF CASH FLOWS THE GROUP THE GROUP THE GROUP THE GROUP Unaudited Unaudited Unaudited Audited 9 MONTHS 9 MONTHS 6 MONTHS 12 MONTHS 30 NOVEMBER 30 NOVEMBER 31 AUGUST 28 FEBRUARY 2018 2017 2018 2018 USD USD USD USD Net Cash (used in)/ from other operating activities (68 054) 290 453 95 717 187 623 Cash from/(used in) investing activities Property, plant and equipment 226 817 (77 964) 5 749 2 303 Movement in net cash resources 158 763 212 489 101 476 189 926 Balance at the start of the year 572 724 386 796 627 292 382 798 Balance at the end of the period 731 487 599 285 728 768 572 724 STATEMENT OF CHANGES IN EQUITY Share Revenue Total USD USD USD Balance as at 31 August 2018 34 965 300 (11 890) 34 953 410 Balance as at 28 February 2018 34 965 300 (486 536) 34 478 764 Total Comprehensive Income for the period - 697 152 697 152 Balance as at 30 NOVEMBER 2018 34 965 300 210 616 35 175 916 SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2018 Health Frail care Products Property Associate Total USD USD USD USD Statement of net profit/loss Revenue 1 857 712 522 677 114 839 2 495 228 Interest expenses - (312 403) - (312 403) Income Tax - - - - Net profit/(loss) for the period 372 039 210 274 114 839 697 152 Statement of financial position Total Assets 29 945 837 7 519 566 849 095 38 314 498 Total Borrowings (720 434) (3 487 325) - (4 207 759) SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2017 Frail care Nutraceutical Property Associate Total USD USD USD USD Statement of net profit/loss Revenue 926 717 546 134 95 612 1 568 463 Interest expenses - 213 192 - 213 192 Income Tax - - - - Net profit/(loss) for the period 136 189 320 822 95 612 552 623 Statement of financial position Total Assets 29 582 209 6 802 678 998 538 37 383 425 Total Borrowings - (2 988 122) - (2 988 122) SEGMENTAL REPORTING – 6 MONTHS ENDED 31 AUGUST 2018 Frail care Nutraceutical Property Associate Total USD USD USD USD Frail care Statement of net profit/loss Revenue 848 453 343 961 78 569 1 270 983 Interest expenses (79 556) (127 425) - (206 981) Income Tax Net profit/(loss) for the period 768 897 216 536 78 569 1 064 002 Statement of financial position Total Assets 29 882 155 7 519 566 849 095 38 250 816 Total Borrowings 1 212 348 2 212 436 - 3 424 784 SEGMENTAL REPORTING – 3 MONTHS ENDED 30 NOVEMBER 2018 Frail care Nutraceutical Property Associate Total USD USD USD USD Statement of net profit/loss Revenue 1 009 259 178 716 36 270 1 224 245 Interest expenses (79 556) (184 978) - (264 534) Income Tax - - - - Net profit/(loss) for the period 929 703 (6 202) 36 270 1 118 823 Statement of financial position Total Assets 29 945 837 7 519 566 849 095 38 314 498 Total Borrowings (720 434) 3 487 325 - (4 207 759) SEGMENTAL REPORTING – 12 MONTHS ENDED 28 FEB 2018 Frail care Nutraceutical Property Associate Total USD USD USD USD Statement of net profit/loss Revenue 887 097 741 551 190 565 1 819 213 Interest expenses - (71 064) - (71 064) Income Tax - (105 970) - (105 970) Net profit/(loss) for the period (179 637) 564 517 190 565 1 642 17 Statement of financial position Total Assets 29 882 155 7 519 566 849 095 38 250 816 Total Borrowings - (3 424 784) - (3 424 784) Notes The Company is required to publish financial results for the 9 months ended 30 November 2018 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited consolidated financial statements for the 3 months ended 30 November 2018 (“Financial Statements”) have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards (“IFRS”), the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listing Requirements. The accounting policies adopted in the preparation of the Financial Statements are in terms of IFRS and are consistent with those applied in the preparation of the audited financial statements of the year ended 28 February 2018. Copies of the abridged unaudited consolidated financial statements for the 9 months ended 30 November 2018 and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request to the Company Secretary at the registered office of the Company at 5th Floor, Atchia Building, Cnr Suffren & Eugene Laurent Streets, Port Louis 21001, Mauritius. This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.20 and section 88 of the Securities Act of Mauritius 2005. The Board accepts full responsibility for the accuracy of the information contained in these Financial Statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 30 November 2018 that require any additional disclosure or adjustment to the Financial Statements. Go Life has its primary listing on the Stock Exchange Mauritius and a secondary listing on the AltX of the JSE. By order of the Board 31 January 2019 For further information please contact: FinAegis Ltd (230) 213-2503 Executive Directors: Non-Executive Directors: Gerhard Jacobus Naudè Mohamed Yusuf Sooklall Marthinus Johannes Wolmarans Jean Daniel Laurent Paulin Marie JSE Sponsor: Company Secretary: Arbor Capital Sponsors (Pty) Ltd FinAegis Ltd Date: 31/01/2019 03:35:00 Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE'). The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct, indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on, information disseminated through SENS.